Extending the curve: survival of EGFR-mutated lung cancer patients in the 21st century.

Lung cancer remains the most lethal malignancy worldwide (1,2). Although incidence rates have decreased in part of the developed world, other regions face the challenge of an epidemic of paramount importance, which is likely to take hundreds of thousands of lives in the coming years (2,3).

[1]  Ying Cheng,et al.  Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[2]  Ying Cheng,et al.  Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. , 2017, The Lancet. Oncology.

[3]  S. Novello,et al.  The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613. , 2017, Clinical lung cancer.

[4]  A. Cardona,et al.  The safety of afatinib for the treatment of non-small cell lung cancer , 2016, Expert opinion on drug safety.

[5]  Sarah L. Greig,et al.  Osimertinib: First Global Approval , 2016, Drugs.

[6]  T. Betsuyaku,et al.  In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancer , 2015, Oncotarget.

[7]  L. Borsu,et al.  Acquired Resistance of EGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor: Emergence of a Third Mutation (C797S) in the EGFR Tyrosine Kinase Domain. , 2015, JAMA oncology.

[8]  Thomas J. Smith,et al.  Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  S. Jois,et al.  Current and future targeted therapies for non-small-cell lung cancers with aberrant EGF receptors. , 2015, Future oncology.

[10]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[11]  F. Collins,et al.  A new initiative on precision medicine. , 2015, The New England journal of medicine.

[12]  R. Perez-Padilla,et al.  [National consensus of diagnosis and treatment of non-small cell lung cancer]. , 2013, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[13]  G. Silvestri,et al.  One hundred years of lung cancer. , 2005, American journal of respiratory and critical care medicine.

[14]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[15]  Scaling up cancer diagnosis and treatment in developing countries: what can we learn from the HIV/AIDS epidemic? , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.